Atara Biotherapeutics (ATRA) Return on Sales (2022 - 2026)

Atara Biotherapeutics has reported Return on Sales for 5 years, with the latest figure at 0.08% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales fell 8.0% year-over-year to 0.08%; the trailing twelve-month figure through Mar 2026 stood at 0.02% (down 2.0% YoY), and the FY2025 full-year result was 0.0%, up 1.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.08%, up from 0.23% in the prior quarter.
• The five-year high for Return on Sales was 0.0% in Q1 2025, with the low at 3.38% in Q4 2022.
• Historically, Return on Sales has averaged 0.36% across 5 years, with a median of 0.05% in 2025.
• The largest YoY upside for Return on Sales was 325 bps in 2023 against a maximum downside of 90 bps in 2023.
• Atara Biotherapeutics' Return on Sales stood at 3.38% in 2022, then soared by 96 bps to 0.12% in 2023, then soared by 97 bps to 0.0% in 2024, then plunged by 5747 bps to 0.23% in 2025, then surged by 65 bps to 0.08% in 2026.
• The last three Return on Sales figures came in at 0.08% (Q1 2026), 0.23% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.